Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allarity Therapeutics Inc ALLR

Healthcare Biotechnology
Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the... see more

Recent & Breaking News (NDAQ:ALLR)

Shareholder Rights Law Firm Robbins LLP Encourages Allarity Therapeutics, Inc. Stockholders with Large Losses to Contact the Firm for Information About the ALLR Securities Class Action

Business Wire September 27, 2024

The Schall Law Firm Encourages Stockholder Participation In A Securities Fraud Case Against Allarity Therapeutics, Inc.

Accesswire September 27, 2024

ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

PR Newswire September 27, 2024

SHAREHOLDER ACTION REMINDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Accesswire September 27, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLR

Accesswire September 27, 2024

ALLR Stockholders Have Opportunity to Lead Allarity Therapeutics, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!

Accesswire September 27, 2024

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Should Contact The Schall Law Firm

Accesswire September 26, 2024

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Newsfile September 26, 2024

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALLR

Newsfile September 26, 2024

ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Newsfile September 26, 2024

ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire September 26, 2024

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!

Accesswire September 26, 2024

The Schall Law Firm Invites Shareholders To Take Part In A Securities Fraud Case Against Allarity Therapeutics, Inc.

Accesswire September 25, 2024

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALLR

Newsfile September 25, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLR

PR Newswire September 25, 2024

ALLR INVESTOR ALERT: Edelson Lechtzin LLP Reminds Allarity Therapeutics, Inc. (NASDAQ: ALLR) Shareholders About the Lead Plaintiff Deadline in the Pending Securities Fraud Class Action

Accesswire September 25, 2024

ALLR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

Accesswire September 25, 2024

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Impacted Investors Are Urged To Contact The Schall Law Firm

Accesswire September 24, 2024

Allarity Therapeutics, Inc Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Allarity Therapeutics, Inc.

PR Newswire September 24, 2024

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Newsfile September 24, 2024